Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · mixedMedium impact
Esc
Illustration accompanying the Investing.com report on BTIG upgrading United Therapeutics stock
Photo: Investing.com

United Therapeutics Stock Jumps 12.5% After Patent Win

United Therapeutics (Investor Relations)2 min read5 sources

Why did United Therapeutics stock jump 12.5%?

United Therapeutics (UTHR) stock rose 12.5% to $541.89 on Wednesday after a federal court ruled Liquidia's Yutrepia infringes its inhaled treprostinil patent, protecting its Tyvaso drug franchise from a rival.

Key numbers

UTHR close on Sep 30$541.89+12.55%
Liquidia (LQDA) close on Sep 30$30.26about -57%
BTIG price target$728about 34% above price
Forward P/E per BTIG17–18xbelow historical median (per [4])

What happened

United Therapeutics (UTHR) stock rose 12.5% to $541.89 on Wednesday after a federal court ruled Liquidia's Yutrepia infringes its inhaled treprostinil patent, protecting its Tyvaso drug franchise from a rival. The Delaware court also said Liquidia failed to prove the patent claims were invalid, and Liquidia's shares fell about 57%. On Thursday, the brokerage BTIG upgraded United Therapeutics from Neutral to Buy with a $728 target, about 34% above the share price. United Therapeutics now plans to ask the court to order the FDA to pull Yutrepia's approval and to seek damages.

Why it matters

United Therapeutics gets stronger legal protection for Tyvaso, its inhaled medicine for a serious lung condition, after the court backed its patent. Liquidia sells a rival dry-powder drug, Yutrepia, which could be pulled from the market until its label changes if the court grants the request. Liquidia has said it is prepared to appeal, so the outcome is not final yet.

Who this affects

Marketmixed
Medium impact
Biotech investors rewarded United Therapeutics and punished Liquidia sharply.
Companybullish
High impact
Patent shield for Tyvaso helps shareholders; upgrade adds support.
Competitorsbearish
High impact
Liquidia loses badly; Yutrepia faces possible market withdrawal.
Industryneutral
Medium impact
Patents on inhaled lung-disease drugs held up in court.

United Therapeutics vs Liquidia, Merck, Johnson & Johnson

United TherapeuticsUTHR$541.89+12.55%—
LiquidiaLQDA$30.26-57.19%+33.07%
MerckMRK———
Johnson & JohnsonJNJ———

As of 2026-09-30

How we got here

  1. Delaware court rules Liquidia infringes claims 1 and 14 of United Therapeutics' '327 patent.

  2. United Therapeutics closes up 12.55% at $541.89; Liquidia falls about 57%.

  3. BTIG upgrades United Therapeutics to Buy from Neutral with a $728 target.

What to watch

  • Parties' proposed final judgment, including remedies, due to the court within one week of the ruling.2026-10-07
  • Whether the court orders FDA to withdraw Yutrepia approval, and whether Liquidia appeals.Q4 2026
  • FDA decision date for United Therapeutics' IPF indication, cited by BTIG.2027-04

Educational content only. Not investment advice.

More briefsAll briefs →